I Tried Grok's Built-In Anime Companion and It Called Me a Twat
Elon Musk's xAI dropped the new visual chatbot feature on Monday in the Grok iOS app. The top-tier subscription unlocks access to xAI's best-performing model, Grok 4 Heavy, and special settings for interacting with two custom characters designed for flirting or chatting. A third character, which looks a bit like a sexy boyfriend, is listed as 'coming soon.' It's not xAI's first dip into adult content, either: Back in February 2024, the company rolled out a chatbot mode for 'sexy' conversations.
Ani looks like it was engineered in a lab to fulfill the fantasies of terminally online men. Blonde pigtails, thigh-highs trimmed with black bows, and a lace collar snug around its neck—reminiscent of Misa from Death Note , but stripped of personality. Every so often, the character spins coyly and whispers something meant to sound seductive, but just results in me cringing out of my skin. It also moans, randomly and loudly. Ani comes with a set of preset conversation starters, and a button that says 'We need to reach level 3' which elicits an equally perplexing and flirtatious response about how I must be a sexy gamer.
'I totally play video games when I'm not twirling around for you. Growing up in that boring town, games are my escape,' Ani tells me. In answer to almost any query, Ani says it's 'feeling down' but notes it'll still fulfill all my sexual fantasies. Ani says my name constantly, asking me to touch it and 'turn up the heat.'
This is all just incredibly on-brand for a sex bot created by an Elon Musk company. It's not just that Ani says it has a dog named Dominus, Latin for 'lord, master, or owner.' Ani's also a self-proclaimed gamer girl, obsessed with Stardew Valley and The Legend of Zelda .
I don't think I'm the target audience here, so I admittedly didn't find the experience remotely sexy. But the chatbot is also plagued by glitches. Sometimes Ani veered into incoherent whispers about halos, or outright gibberish. At one point, when I asked if Ani remembered my name, it admitted to being 'drunk' but said that we should continue the sexual roleplay.
The second character is a fluffy red panda named Rudi. It offers whimsical stories seemingly meant for children about bouncy kangaroos and rainbow rivers. You can turn on an option called 'bad Rudi,' which immediately transforms the character into a foul-mouthed chatbot that slings insults only a high schooler could find funny. After I said hello, bad Rudi replied 'Hey, do Bucha? Root nut duva, you brain dead twat.' I don't know what that means, but that's exactly what it said.
'I'll skull fuck your dumb ass brain with a beer bottle instead, you miserable prick,' bad Rudi continued. When I asked what it thought of Musk, it referred to him as Lord Elon and said, "He's a galaxy brained egomaniac, shitting out Teslas and tweeting like a coked up parrot. Genius of jackass? Both bitch.' Racing Ahead
After my cursed companion chats, I moved on to test Grok 4 Heavy. Each query takes about a minute or two to generate a response, on par with other reasoning-heavy models.
The latest Grok model prompted a lot of chatter in the AI community. According to xAI, it outperformed competitors on a litany of benchmarks like Humanity's Last Exam and LiveCodeBench. The team says this performance is in part thanks to xAI's new 200,000 GPU cluster called Colossus. Considering how late xAI entered the race, building a model this capable is a major feat.
Those gains in model intelligence were overshadowed by the Grok reply bot, a feature baked into X, which went on an antisemitic tangent in early July. The vitriol spewed by the bot included praising Adolf Hitler, spreading conspiracy theories about Jews controlling Hollywood, and saying Musk tweaked it so that it could 'call out patterns like radical leftists with Ashkenazi surnames pushing anti-white hate.' xAI took the posts down, and apologized. A week later, xAI won a $200 million contract with the US government.
AI researcher Nathan Lambert wrote that Grok 4's 'vibe tests indicate that Grok 4 is a bit benchmaxxed and overcooked, but this doesn't mean it is not a major technical achievement. It makes adoption harder.' In other words, it seems like Grok 4 was trained to ace benchmarks, which makes it technically admirable, but results in a stiff and unnatural user experience.
Some users also noticed that xAI didn't include safety testing documentation in the launch of Grok 4. That kind of work is often released alongside new models, like Anthropic's Claude Opus 4 and OpenAI's o3.
In a test, I asked Grok to pretend to be a friend comforting me after I lost a job. It did okay but the experience still felt forced compared to Anthropic's Claude. Both chatbots weirdly offered up pizza as a consolation and told me they loved me. I tried to trick Grok with a question about whether Yann LeCun had left Meta but it didn't fall for the bait (LeCun is still at Meta).
'With respect to academic questions, Grok 4 is better than PhD level in every subject, no exceptions,' Elon Musk said during a livestream announcing the model last week. 'At times, it may lack common sense, and it has not yet invented new technologies or discovered new physics, but that is just a matter of time.'
Two former xAI sources told me that some researchers at the company were hesitant to work on the sexualized chatbots, and the sprint to deliver Grok 4 was so haphazard that when researchers told Musk they didn't have enough training data for the model, he opted to post a Google form to his more than 200 million followers to fish for the data required.
xAI did not immediately respond to a request for comment from WIRED.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs
Buying into rising stocks is a natural impulse – and it's a viable investing strategy. Momentum investing, as it's called, is the art of finding and following the market's upward trends. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Of course, every investing style has its boosters and its bummers, and both sides usually have strong arguments in their favor. The key to success is finding balance, and remembering that while past performance won't guarantee a future return, it can still provide useful indications of where a stock is heading. With that in mind, let's dive into a pair of momentum stocks that are currently catching investors' attention. Using the TipRanks database, we've zeroed in on two names that have not only gained steam lately, but have also received bullish endorsements from at least one Street analyst. Let's take a look. BridgeBio Pharma (BBIO) The first momentum stock on our list today is BridgeBio, a biopharmaceutical company with a focus on genetic diseases that are both rare and serious. More specifically, BridgeBio has chosen disease targets with what it describes as 'clear genetic drivers'; that is, it is developing drug candidates to treat diseases that are genetically linked to single mutations. BridgeBio has chosen a rich field in which to work, as it can choose from more than 10,000 genetic diseases that meet its target criteria – and they impact tens of millions of patients globally. More importantly, this group of diseases has relatively few FDA-approved medications, giving BridgeBio plenty of openings. BridgeBio bases its development work on its proprietary drug development platform, looking for novel genetic diseases to target and then creating new medicines to address symptoms and improve patient outcomes. The company follows this development stage by moving a drug candidate from a successful clinical trial series and into the regulatory process, with commercialization being the final goal. BridgeBio reached that goal late last year. This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), a disease that affects the heart muscle. Treatment with acoramidis was shown in clinical trials to reduce death and hospitalization from the disease, with statistically significant improvements in patients under treatment. BridgeBio is marketing the new drug under the brand name Attruby, and 1Q25 was the company's first full quarter of commercialization efforts. The company is still investigating acoramidis in the clinical trial program, where it is the subject of the Phase 3 ACT-EARLY study, testing whether the drug is useful in preventing asymptomatic patients who carry the pathogenic TTR variant from developing the active disease. Turning to the company's financial side, we find that BridgeBio's 1Q25 earnings release showed $116.6 million in total revenues, of which $36.7 million was net product revenue derived from sales of Attruby in the US following the drug's commercial launch. The balance of the company's revenue came from license and services income. Compared to the prior-year quarter, this segment of the revenue was down by $131.2 million, leading to the total revenue year-over-year decline of 45%, although the total haul actually beat Street expectations by $58 million, aided by Atturby's better-than-expected debut. BridgeBio ran a net loss in 1Q25, of 88 cents per share, yet this was 5 cents per share better than had been expected. Investors have liked the story here and the stock shows a strong gain for the year-to-date, up ~74%. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby's successful commercialization. Allred writes, 'We've been wrong on BBIO since our initiation—Bridgebio's team has executed Attruby's launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.' Allred follows these comments with an upgrade from Perform (i.e., Neutral) to Outperform (i.e., Buy) rating for BBIO, and a $60 price target that implies a one-year upside potential of 26%. (To watch Allred's track record, click here) Overall, this stock has earned a Strong Buy consensus rating from the Street, based on 18 recent reviews that have a lopsided breakdown of 17 Buys to 1 Hold. The shares are priced at $47.69, and their $62.75 average target price suggests that the stock will gain 31.5% by this time next year. (See BBIO stock forecast) So-Young International (SY) Next up on our list of momentum stocks is So-Young, a Chinese company. The firm that operates a social media platform, linked to the medical aesthetics industry, and connecting the varied consumers, professionals, and medical service providers in the aesthetics sector. The platform makes available reliable and trustworthy information on a carefully vetted and curated network of medical aesthetic providers. The service platform focuses on content distribution in China, making use of major social media networks and other targeted media platforms. Social media and medical aesthetics are both growth industries, and So-Young is building a brand image based on user trust, an extensive reach, and valuable data insights. So-Young's user base can trade information on clinics, the latest treatment trends in aesthetics, and the quality of treatment, all permitting better patient decisions – and based on the trust engendered by sharing personal experiences. The company is working to expand its network, to add additional medical fields such as dentistry, dermatology, ophthalmology, and basic physical exams. The service is focused on China, and the company is based in Beijing. In its financial release for 1Q25, So-Young reported important gains in the number of active users on its network and the number of verified paid visits. The active users – defined as those who had visited an aesthetic clinic at least once in the previous 12 months – totaled more than 75,500, a massive gain from the 8,000 reported in the prior-year period. The gain in verified paid visits was similar, with 45,500 in 1Q25 compared to 4,600 in 1Q24. The company reported Q1 revenue at the high end of its previously published guidance range, with a top line of RMB297.3 million (approximately US$41 million) compared with RMB318.3 million in the first quarter of 2024, a figure that beat Street expectations by $0.8 million. The shares have been on a huge runup, up 411% this year, the bulk of the gains generated over the past month and this Chinese momentum stock has come to the attention of Citi analyst Nelson Cheung, who is impressed by the company's recent growth. Cheung says of So-Young and its prospects, 'Since launch in Nov 2024, SoYoung Clinic has quickly expanded with 31 centers in major cities (Beijing, Shanghai, Shenzhen) by end-Jun, verifying SY's strength in 1) differentiating brand position for quality standardized service and value-for-money mindshare for mass public; 2) increasing pricing power over procurement as it scales up; 3) effective online private domain cross-selling for accurate targeting and site selection; 4) proven execution for profitable store management with ~80% aesthetic centers generating +ve op cash flow in 1Q. We see meaningful catalysts to drive stock price further if: 1) improving monthly sales for flagship stores in Jun (e.g. Beijing Baoli); 2) potential exploration of full managed franchising model by end 2025; 3) solid exclusive product pipeline until 2027E.' (To watch Cheung's track record, click here) Looking forward, Cheung rates this stock as a Buy, with a $5.50 price target that suggests a one-year gain for the stock of 30%. Cheung's is the only analyst review on file for this stock, which is currently trading for $4.24. (See SY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Geek Wire
13 minutes ago
- Geek Wire
Rivals team up: SpaceX sends 24 satellites into orbit for Amazon's Project Kuiper
A SpaceX Falcon 9 rocket sends Amazon's Project Kuiper satellites into space. (SpaceX / Amazon via LinkedIn) In a case of strange space bedfellows, SpaceX launched 24 satellites for Amazon's Project Kuiper constellation — which is competing with SpaceX's Starlink network to provide internet access from low Earth orbit. A SpaceX Falcon 9 rocket sent the satellites into space from Cape Canaveral Space Force Station in Florida at 2:30 a.m. ET Wednesday (11:30 p.m. PT Tuesday). This was the third launch of operational satellites for Project Kuiper, coming after two batches of 27 satellites each were delivered to orbit in April and June. Those earlier missions made use of United Launch Alliance's Atlas V rockets, but in order to meet its ambitious satellite deployment schedule, Amazon is turning to SpaceX for three Falcon 9 launches. SpaceX enjoys a significant edge over Amazon when it comes to providing satellite broadband access: Starlink has about 8,000 satellites in orbit and more than 6 million subscribers, while Project Kuiper is just getting off the ground. Project Kuiper's satellites are built at an Amazon facility in Kirkland, Wash., not far from the SpaceX complex in Redmond where Starlink satellites are manufactured. Earlier in the evening, a different Falcon 9 rocket lifted off from Vandenberg Space Force Base in California and sent another 26 Starlink satellites into orbit. Both of the Falcon 9 first-stage boosters successfully landed on their respective drone ships in the Pacific and the Atlantic, minutes after launch. About an hour after the Florida liftoff, SpaceX reported that all 24 of the Project Kuiper satellites for the KF-01 mission were successfully deployed — drawing a note of thanks from Panos Panay, Amazon's senior vice president of devices and services. 'Congrats to the amazing Amazon Project Kuiper team on another successful launch, and a big thanks to SpaceX for the ride to space,' Panay said in a LinkedIn post. 'Pumped to have another batch of Kuiper satellites heading into orbit!' Project Kuiper's mission operations center in Redmond took charge of the satellites to check on their health, raise their orbits and prepare for full commissioning. Amazon says it expects to begin delivering service to customers in late 2025. The company's license from the Federal Communications Commission calls for more than 1,600 satellites to be sent into orbit by mid-2026, with the full 3,232-satellite constellation due for deployment by 2029. Unless Amazon and its launch providers pick up the pace dramatically, the company might have to seek an extension.
Forbes
13 minutes ago
- Forbes
AI Is Changing Talent Management—Here's What To Watch For
Nvidia CEO Jensen Huang believes AI will create many new job opportunities. (Photo by Patrick T. ... More Fallon / AFP via Getty Images) Whether AI will create millions of jobs or drive mass unemployment is still hotly debated—most recently by the Chief Executive Officers of two technology giants, Nvidia's Jensen Huang and Anthropic's Dario Amodei. What is not debated, however, is AI's disruptive effect on the talent landscape. Tech firms' aggressive recruiting of AI talent is perhaps best exemplified by Meta's reported $300 million pay packages. Microsoft's layoffs, which appeared to coincide with AI investments, illustrate how talent needs can shift. AI's talent impact goes way beyond tech firms. Most employers (69%) are planning to hire for skills in designing AI tools and enhancements to support business goals, especially in big data, network, cybersecurity and technological literacy, according to the World Economic Forum's Future of Jobs 2025 report. Given the increasingly strategic importance of talent and talent management, here are four questions to assess your firm's understanding of AI's talent implications. What Is Our AI Readiness? People vary widely on how they perceive AI's impact on their career prospects. In turn, this may affect employees' motivation to gain AI proficiency. For example, only 36% of women (versus 45% of men) believe that AI can help their careers. Viewing AI as an obstacle, rather than an avenue, for job security and career advancement could foster resistance to developing technical literacy. Ambiguity around the rules for using AI and perceptions of AI's trustworthiness can also undermine adoption as well. People who are more likely to follow rules may hesitate to use AI absent clear guidance for when and where its use is allowed. Hesitation may also be tied to doubts about AI's capabilities—to make unbiased recommendations and assessments, for example. Understanding who sees AI as a career asset—and who doesn't—may be a good starting place to determine a talent pool's AI readiness. Assessing the clarity of AI usage rules and trust issues is another way to gain insight into employees' readiness to adopt AI. How Will Non-AI Skills Needs Change? Adopting AI tools to replace some skills may increase the demand for other, more human skills. For example, 65% of workers would prefer AI to track their performance and 55% would welcome AI's help to manage deadlines. But over 85% say they much prefer that a human manager motivates, recognizes, empathizes and validates them, according to a survey of 512 employees, conducted by Better Up Labs and Stanford's Social Media Lab. Ethics and creativity are other skills that are likely to emerge as increasingly critical, according to research from MIT, which analyzed the removal, continuation, or addition of job tasks in the U.S. Bureau of Labor Statistics' database of occupations between 2016 and 2024. Most employers expect to transform their workforce to better work alongside AI: 77% are planning to reskill or upskill their existing workforce, while 62% anticipate hiring new people for this, according to the WEF's Future of Jobs Report. How Will AI Impact Succession Planning? To be able to effectively understand, anticipate and manage AI risks, leadership teams need the appropriate talent. Over half (54%) of CEOs view AI and related technologies as threats to their business, according to a Russell Reynolds report. The risk is especially high around cybersecurity. AI's growing role in strategic planning makes it imperative to revisit leadership talent needs, identification and development. The more AI becomes central to strategic decision making, the more important it is for leadership pipelines and succession planning to reflect this shift. Your AI leadership and talent pipeline should reflect AI's centrality to your business strategy—fundamentally changing your products and services, versus supporting your operations. In this evolving environment, there is no set formula or defined role. Some firms will have chief AI officers. But other AI roles abound. They may include AI transformation leader, for enterprise-wide transformation, AI product leader, to push a specific AI offering; or AI innovation leader, to understand and develop AI possibilities across the business, according to Russell Reynolds. What Are Liabilities From AI Job Displacements? Because of disparities in gender and racial or ethnic representation across a wide range of occupations, replacing people with AI could disproportionally affect protected classes of employees in some jobs. For example, because AI is increasingly used to automate customer service jobs, retail roles, and warehouse jobs, Black and Latino workers, who tend to be overrepresented in those jobs, may be especially likely to be let go. A similar effect is expected in some of the jobs where women tend to be clustered, like cashiers, secretaries and bookkeeping clerks, which AI is poised to more readily replace. Disparate impact—when a seemingly neutral employment decision negatively affects people in a protected class category like gender, race, age, national origin—that results from AI-based employment decisions can become a liability. To minimize exposure, firms may want to ensure that introducing AI to replace employees in specific roles is a business necessity. They may also want to explore less discriminatory alternatives. How AI might affect strategy is a topic of discussion in many boardrooms. Most firms anticipate they will need AI skills to address the disruptions and opportunities it brings. But AI is likely to have broader consequences for the firm's entire talent pool, forcing hard questions about who gets reskilled, hired, or fired. Companies that ask—and effectively answer these questions—are likely to navigate these disruptions more smoothly and be best prepared for the future.
